HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.

Abstract
Muraglitazar, a PPARalpha/gamma agonist, dose-dependently increased urinary bladder tumors in male Harlan Sprague-Dawley (HSD) rats administered 5, 30, or 50 mg/kg/day for up to 2 years. To determine the mode of tumor development, male HSD rats were treated daily for up to 21 months at doses of 0, 1, or 50 mg/kg while being fed either a normal or 1% NH4Cl-acidified diet. Muraglitazar-associated, time-dependent changes in urine composition, urothelial mitogenesis and apoptosis, and urothelial morphology were assessed. In control and treated rats fed a normal diet, urine pH was generally > or = 6.5, which facilitates formation of calcium-and magnesium-containing solids, particularly in the presence of other prolithogenic changes in rat urine. Urinary citrate, an inhibitor of lithogenesis, and soluble calcium concentrations were dose dependently decreased in association with increased calcium phosphate precipitate, crystals and/or microcalculi; magnesium ammonium phosphate crystals and aggregates; and calcium oxalate-containing thin, rod-like crystals. Morphologically, sustained urothelial cytotoxicity and proliferation with a ventral bladder predilection were noted in treated rats by month 1 and urinary carcinomas with a similar distribution occurred by month 9. Urothelial apoptotic rates were unaffected by muraglitazar treatment or diet. In muraglitazar-treated rats fed an acidified diet, urine pH was invariably < 6.5, which inhibited formation of calcium-and magnesium-containing solids. Moreover, dietary acidification prevented the urothelial cytotoxic, proliferative, and tumorigenic responses. Collectively, these data support an indirect pharmacologic mode of urinary bladder tumor development involving alterations in urine composition that predispose to urolithiasis and associated decreases in urine-soluble calcium concentrations.
AuthorsMark A Dominick, Melvin R White, Thomas P Sanderson, Terry Van Vleet, Samuel M Cohen, Lora E Arnold, Marty Cano, Sarah Tannehill-Gregg, Jeffrey D Moehlenkamp, Crystal R Waites, Beth E Schilling
JournalToxicologic pathology (Toxicol Pathol) Vol. 34 Issue 7 Pg. 903-20 ( 2006) ISSN: 0192-6233 [Print] United States
PMID17178691 (Publication Type: Journal Article)
Chemical References
  • Antimetabolites
  • Carcinogens
  • Citrates
  • Electrolytes
  • Oxalates
  • Oxazoles
  • PPAR alpha
  • PPAR gamma
  • Phosphates
  • Bromodeoxyuridine
  • Calcium
  • Glycine
  • muraglitazar
Topics
  • Animals
  • Antimetabolites
  • Apoptosis (drug effects)
  • Area Under Curve
  • Bromodeoxyuridine
  • Calcium (urine)
  • Carcinogens
  • Cell Proliferation (drug effects)
  • Citrates (urine)
  • Electrolytes (urine)
  • Glycine (analogs & derivatives, pharmacokinetics, toxicity)
  • Hydrogen-Ion Concentration
  • Immunohistochemistry
  • Male
  • Microscopy, Electron, Scanning
  • Organ Size
  • Oxalates (urine)
  • Oxazoles (pharmacokinetics, toxicity)
  • PPAR alpha (agonists)
  • PPAR gamma (agonists)
  • Phosphates (urine)
  • Proteinuria (chemically induced)
  • Rats
  • Rats, Sprague-Dawley
  • Spectrometry, X-Ray Emission
  • Urinary Bladder Neoplasms (chemically induced, pathology)
  • Urolithiasis (chemically induced, pathology)
  • Urothelium (pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: